• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Novartis Acquires Avrobio’s $88M Gene Therapy

Article

Purchase leaves biotech’s remaining assets on the table.

Genetic engineering and gene manipulation concept. Hand is replacing part of a DNA molecule. Image Credit: Adobe Stock Images/vchalup

Image Credit: Adobe Stock Images/vchalup

Novartis, a global healthcare company, has officially reached an agreement with Avrobio, a biotech organization, to acquire AVR-RD-04, an investigational hematopoietic stem cell gene therapy program for the treatment of the rare genetic condition cystinosis. Per the deal, Novartis will pay $87.5 million without committing milestones or royalties to land the clinical-phase asset. This announcement comes after an initial report of the healthcare company preparing for a full takeover.

The deal represents pressure currently facing Avrobio. With its stock trading below $1 in recent months, the biotech’s ability to raise more money from investors is limited, leading it to identify the Novartis deal as a way to boost its bank balance while narrowing its pipeline.

Reference: Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf. May 22, 2023/ Fierce Biotech

Related Videos
Related Content